Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$500.0K+19900.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- J. D. Finley
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- 1.55
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 25.33
Financials
Revenue
$500.0K+19900.0%Net Income
$-10.57MEBITDA
$-10.57MFree Cash Flow
$-7.60MEPS (diluted)
$-0.05Shares Outstanding (diluted)
211.38M+159403.5%Operating Expenses
$12.20MCash & Debt
$125.17MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-16.78M | $-0.30 |
| 2024 | $0.00 | $-14.44M | $-10.19 |
| 2023 | $250.0K | $-12.30M | $-27.01 |
| 2022 | $0.00 | $-14.26M | $-16.53 |
| 2021 | $0.00 | $-26.62M | $-2144.25 |
| 2020 | $0.00 | $-10.32M | $-186.00 |
| 2019 | $15.4K | $-8.35M | $-14.78 |
| 2018 | $260.0K | $-4.92M | $-18.02 |
| 2017 | $260.0K | $-15.67M | $-71.59 |
| 2016 | $16.2K | $-21.07M | $-126.11 |
| 2015 | $10.4K | $-20.90M | $-197.36 |
| 2014 | $18.8K | $-22.63M | $-225.20 |
| 2013 | $110.0K | $-19.83M | $-237.79 |
| 2012 | $407.7K | $-10.12M | $-150.85 |
Valuation
PALIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-9.09%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·8d ago·Neutral
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026 Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn's disease
View source ↗ - Newsmarketbeat.com·8d ago·Negative
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's Palisade Bio NASDAQ: PALI said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn's disease after completing its Phase I program.
View source ↗ - Newsglobenewswire.com·14d ago·Negative
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn's disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028 Phase 2 program builds on clinical experience in fibrostenotic Crohn's disease demonstrating targeted tissue exposure, PDE4 target engagement and encouraging endoscop…
View source ↗ - Newsglobenewswire.com·15d ago·Negative
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum Presentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that JD Finley, Chief Executive Officer, and Mitchell Jones, M.D.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·33d ago·Negative
Palisade Bio to Participate in Upcoming Investor Conferences Denver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that members of management will participate in three healthcare investor conferences in September 2026.
View source ↗ - Newsdefenseworld.net·50d ago·Positive
Brokerages Set Palisade Bio, Inc. (NASDAQ:PALI) Price Target at $9.00 Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) has received a consensus rating of "Buy" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have given a strong buy recommendation to the
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.06 per share
Typical surprise -20.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.05 vs $-0.05beat
- Tue, May 12$-0.05 vs $-0.04miss
- Mon, Mar 23$-0.04 vs $-0.02miss
- Mon, Nov 10$-0.38 vs $-0.32miss
- Mon, Aug 11$-0.58 vs $-0.48miss
- Mon, May 12$-0.47 vs $-0.84beat
Estimates and results for PALI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PALI officers and directors.
- Bought
- $278k
- Sold
- $420k
10 trades
4 trades
- Baltera Robert Jr.bought
- Baltera Robert Jr.bought
- Baltera Robert Jr.bought
- Jones Mitchell Lawrencesold
- Finley John Davidsold
- Baltera Robert Jr.bought
- Baltera Robert Jr.bought
- Baltera Robert Jr.bought
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PALI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.